Eslicarbazepine Acetate Tablet
NDC Package 66406-0204-0

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Eslicarbazepine Acetate tablets is eslicarbazepine is used alone or with other medications to treat a certain type of seizure disorder (focal seizures). This formulation utilizes a tablet delivery system. Marketed by Patheon Inc., this product is identified by NDC 66406-0204.

Identification & Billing

NDC Package Code
66406-0204-0
Package Description
21429 TABLET in 1 CONTAINER
Product Code
66406-0204
11-Digit Billing Format
66406020400

Clinical Specifications

Proprietary Name
Eslicarbazepine Acetate
Non-Proprietary Name
Eslicarbazepine Acetate
Substance Name
Eslicarbazepine Acetate
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Active Ingredient(s)
ESLICARBAZEPINE ACETATE 800 mg/1
Usage Information
Eslicarbazepine is used alone or with other medications to treat a certain type of seizure disorder (focal seizures). It belongs to a class of drugs known as anticonvulsants. Eslicarbazepine may reduce the number of seizures you have.

Regulatory & Marketing

Labeler Name
Patheon Inc.
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
04-07-2014
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 66406-0204-0 identifies a specific commercial package of 21429 tablet in 1 container of Eslicarbazepine Acetate (UNFINISHED drug), drug for further processing labeled by Patheon Inc.. This tablet is formulated for use and contains eslicarbazepine acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Patheon Inc. on April 07, 2014. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Eslicarbazepine is used alone or with other medications to treat a certain type of seizure disorder (focal seizures). It belongs to a class of drugs known as anticonvulsants. Eslicarbazepine may reduce the number of seizures you have.

How is this Patheon Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 66406020400. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
66406-0204-0
11-Digit CMS (5-4-2)
66406-0204-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.